--- schema_version: "secwatch.filing_event.v1" accession: "0001510964-23-000026" form_type: "8-K" ticker: "CVSI" cik: "0001510964" company_name: "CV Sciences, Inc." filed_at: "2023-06-05T23:59:59+00:00" generated_at: "2026-06-14T07:18:51.843320+00:00" event_type: "other_material" sentiment: "neutral" materiality_score: 0.4 calibrated_materiality_score: 0.4 confidence: "high" source: SEC EDGAR --- # CV Sciences shareholders approve 2023 Equity Incentive Plan, elect directors ## Summary - Stockholders approved 2023 Equity Incentive Plan (11.7M for, 8.6M against) to replace 2013 Plan. - Elected directors: Dr. Jamie Corroon, Joseph Dowling, Bill McCorkle to serve until next annual meeting. - Ratified Haskell & White LLP as independent auditor for FY2023 (74.7M for, 1.2M against). - Non-binding advisory vote on named executive officer compensation approved (11.8M for, 8.7M against). - Quorum of 50.4% (76.6M of 152.1M shares) present at virtual annual meeting on June 1, 2023. ## SEC filing metadata - accession: 0001510964-23-000026 - form_type: 8-K - ticker: CVSI - cik: 0001510964 - company_name: CV Sciences, Inc. - filed_at: 2023-06-05T23:59:59+00:00 - event_type: other_material - sentiment: neutral - materiality_score: 0.4 - calibrated_materiality_score: 0.4 - confidence: high - sec_items: 5.02, 5.07, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1510964/000151096423000026/0001510964-23-000026-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1510964/000151096423000026/cvsi-20230601.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001510964-23-000026 - JSON: https://secwatch.observer/filing/0001510964-23-000026.json - Plain text: https://secwatch.observer/filing/0001510964-23-000026.txt ## Key facts - Shareholder Votes CV Sciences, Inc. shareholders approved Proposal 3 - Adoption of our 2023 Plan at the 2023-06-01 meeting. - Proposal: equity plan - Outcome: passed - Meeting: 2023-06-01 source text: On June 1, 2023, the Company held the 2023 Annual Meeting in a virtual format. At the close of business on April 3, 2023, the record date for the 2023 Annual Meeting, there were 152,104,789 shares of common stock issued and outstanding, which constituted all of the outstanding capital stock of the Company. At the 2023 Annual Meeting, 76,611,221 of the 152,104,789 outstanding shares of common stock entitled to vote, or approximately 50.4%, were represented by proxy at the meeting, and, therefore, a quorum was present. The proposals voted on at the 2023 Annual Meeting are more fully described in Proxy Statement, which is incorporated herein by reference. The final voting results on the proposals presented for stockholder approval at the 2023 Annual Meeting were as follows: Proposal 1 - Election of Directors The Company's stockholders elected three directors, each to serve until the Company's next Annual Meeting of Stockholders or until his successor is duly elected and qualified, subject evidence_url: https://www.sec.gov/Archives/edgar/data/1510964/000151096423000026/0001510964-23-000026-index.htm - Shareholder Votes CV Sciences, Inc. shareholders approved Proposal 1 - Election of Directors at the 2023-06-01 meeting. - Proposal: director election - Outcome: passed - Meeting: 2023-06-01 source text: On June 1, 2023, the Company held the 2023 Annual Meeting in a virtual format. At the close of business on April 3, 2023, the record date for the 2023 Annual Meeting, there were 152,104,789 shares of common stock issued and outstanding, which constituted all of the outstanding capital stock of the Company. At the 2023 Annual Meeting, 76,611,221 of the 152,104,789 outstanding shares of common stock entitled to vote, or approximately 50.4%, were represented by proxy at the meeting, and, therefore, a quorum was present. The proposals voted on at the 2023 Annual Meeting are more fully described in Proxy Statement, which is incorporated herein by reference. The final voting results on the proposals presented for stockholder approval at the 2023 Annual Meeting were as follows: Proposal 1 - Election of Directors The Company's stockholders elected three directors, each to serve until the Company's next Annual Meeting of Stockholders or until his successor is duly elected and qualified, subject evidence_url: https://www.sec.gov/Archives/edgar/data/1510964/000151096423000026/0001510964-23-000026-index.htm - Shareholder Votes CV Sciences, Inc. shareholders approved Proposal 2 - Ratification of Selection of Independent Registered Public Accounting Firm at the 2023-06-01 meeting. - Proposal: auditor ratification - Outcome: passed - Meeting: 2023-06-01 source text: On June 1, 2023, the Company held the 2023 Annual Meeting in a virtual format. At the close of business on April 3, 2023, the record date for the 2023 Annual Meeting, there were 152,104,789 shares of common stock issued and outstanding, which constituted all of the outstanding capital stock of the Company. At the 2023 Annual Meeting, 76,611,221 of the 152,104,789 outstanding shares of common stock entitled to vote, or approximately 50.4%, were represented by proxy at the meeting, and, therefore, a quorum was present. The proposals voted on at the 2023 Annual Meeting are more fully described in Proxy Statement, which is incorporated herein by reference. The final voting results on the proposals presented for stockholder approval at the 2023 Annual Meeting were as follows: Proposal 1 - Election of Directors The Company's stockholders elected three directors, each to serve until the Company's next Annual Meeting of Stockholders or until his successor is duly elected and qualified, subject evidence_url: https://www.sec.gov/Archives/edgar/data/1510964/000151096423000026/0001510964-23-000026-index.htm - Shareholder Votes CV Sciences, Inc. shareholders approved Proposal 4 - Advisory Vote to Approve Named Executive Officer Compensation at the 2023-06-01 meeting. - Proposal: say on pay - Outcome: passed - Meeting: 2023-06-01 source text: On June 1, 2023, the Company held the 2023 Annual Meeting in a virtual format. At the close of business on April 3, 2023, the record date for the 2023 Annual Meeting, there were 152,104,789 shares of common stock issued and outstanding, which constituted all of the outstanding capital stock of the Company. At the 2023 Annual Meeting, 76,611,221 of the 152,104,789 outstanding shares of common stock entitled to vote, or approximately 50.4%, were represented by proxy at the meeting, and, therefore, a quorum was present. The proposals voted on at the 2023 Annual Meeting are more fully described in Proxy Statement, which is incorporated herein by reference. The final voting results on the proposals presented for stockholder approval at the 2023 Annual Meeting were as follows: Proposal 1 - Election of Directors The Company's stockholders elected three directors, each to serve until the Company's next Annual Meeting of Stockholders or until his successor is duly elected and qualified, subject evidence_url: https://www.sec.gov/Archives/edgar/data/1510964/000151096423000026/0001510964-23-000026-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.